Key terms
About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IONS news
Mar 25
8:28am ET
Ionis Pharmaceuticals to present data from Phase 3 on olezarsen
Mar 18
7:50am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)
Mar 14
7:36am ET
TD Cowen Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Mar 14
5:50am ET
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Ionis Pharmaceuticals (IONS) and Arcellx Inc (ACLX)
Mar 13
7:10am ET
Ionis announces results from Phase 2 study of ION224
Mar 06
8:17am ET
Ionis Pharmaceuticals price target raised to $72 from $65 at Oppenheimer
Mar 06
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Ionis Pharmaceuticals (IONS) and Fusion Pharmaceuticals (FUSN)
Mar 06
7:37am ET
TD Cowen Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
Feb 29
9:22am ET
Ionis Pharmaceuticals Announces Executive Advisory and Leadership Changes
Feb 29
9:11am ET
Ionis Pharma names Kyle Jenne new Chief Global Product Strategy Officer
Feb 29
5:37am ET
Ionis Pharmaceuticals: A Strong Buy on Robust Clinical Program Developments and Competitive Advantages
Feb 26
8:05am ET
Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Feb 25
11:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Feb 22
8:11am ET
Ionis Pharmaceuticals price target raised to $63 from $62 at Piper Sandler
Feb 22
8:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Silver Spike Investment (SSIC) and Ionis Pharmaceuticals (IONS)
Feb 22
7:38am ET
Ionis Pharmaceuticals: A Strong Buy on ATTR Franchise Prospects and Financial Fortitude
Feb 22
7:32am ET
RBC Capital Remains a Buy on Ionis Pharmaceuticals (IONS)
Feb 22
5:40am ET
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Ionis Pharmaceuticals (IONS) and Icon (ICLR)
Feb 22
5:07am ET
Barclays Remains a Hold on Ionis Pharmaceuticals (IONS)
Feb 21
5:05pm ET
Ionis Pharmaceuticals: A Buy Rating Based on Strong Q4 Earnings, Promising Pipeline, and Strategic Market Expansion
Feb 21
4:25pm ET
Ionis Pharmaceuticals: A Strong Buy on Robust Revenue Prospects and Clinical Milestones
Feb 21
7:05am ET
Ionis Pharmaceuticals sees FY24 revenue over $575M, consensus $636.36M
Feb 21
7:03am ET
Ionis Pharmaceuticals reports Q4 EPS (6c), consensus (83c)
Feb 16
5:50am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS) and Nurix Therapeutics (NRIX)
Feb 16
5:29am ET
Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Glaukos (GKOS)
Feb 15
7:15am ET
Ionis Pharmaceuticals confirms FDA orphan designation for olezarsen
Feb 14
7:19pm ET
Ionis Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Feb 14
6:00pm ET
Ionis Pharmaceuticals’ olezarsen granted FDA orphan designation
Feb 14
4:17pm ET
Ionis Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Feb 13
5:37am ET
Ionis Pharmaceuticals Earns Buy Rating from Analyst Yanan Zhu on Bepirovirsen’s Promising Hepatitis B Treatment Prospects
Feb 09
8:10am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
No recent news articles are available for IONS
No recent press releases are available for IONS
IONS Financials
Key terms
Ad Feedback
IONS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IONS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range